Browse hierarchy: [Clinical Chemistry (CH)](/submissions/CH) → [Subpart B — Clinical Chemistry Test Systems](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems) → [21 CFR 862.1223](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/862.1223) → QWZ — Prognostic Test For Assessment Of Chronic Kidney Disease Progression

# QWZ · Prognostic Test For Assessment Of Chronic Kidney Disease Progression

_Clinical Chemistry · 21 CFR 862.1223 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/QWZ

## Overview

- **Product Code:** QWZ
- **Device Name:** Prognostic Test For Assessment Of Chronic Kidney Disease Progression
- **Regulation:** [21 CFR 862.1223](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/862.1223)
- **Device Class:** 2
- **Review Panel:** [Clinical Chemistry](/submissions/CH)

## Identification

KidneyIntelX.dkd is an in-vitro diagnostic test that uses an algorithm to combine clinical variables (blood urea nitrogen (BUN), hemoglobin A1c (HbA1c), and urine albumin creatinine ratio (uACR)) and quantitative measurements of three circulating biomarkers (tumor necrosis factor receptor-1 (TNFR-1), tumor necrosis factor receptor-2 (TNFR-2), and kidney injury molecule-1 (KIM-1)) in human plasma. It is indicated as an aid in the assessment of the risk of progressive decline in kidney function (sustained decrease in eGFR ≥ 40% lasting more than 3 months) within a period of up to 5 years in adult patients with type 2 diabetes and existing chronic kidney disease.

## Classification Rationale

Class II with special controls. The device is classified under 21 CFR 862.1223 as a prognostic test for assessment of chronic kidney disease progression.

## Recent Cleared Devices (1 of 1)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [DEN200052](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/QWZ/DEN200052.md) | KidneyIntelX.dkd | Renalytix Ai, Inc. | Jun 29, 2023 | DENG |

## Top Applicants

- Renalytix Ai, Inc. — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/QWZ](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/QWZ)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com